TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03003065

Intervention type: DRUG
Group type: OTHER
Intervention: Temoporfin
Description: A single treatment with Temoporfin (Foscan) 3 mg given intravenously followed by PDT with laser light at 652 nm (Ceralas, Biolitec, Germany) within 72 hours
Study: NCT02475863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Warfarin Dosing Aid
Description: A pharmacokinetic/pharmacodynamic model-based dosing algorithm for warfarin

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Practice
Description: Warfarin dose adjustments according to standard unit protocol
Study: NCT02244957

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bi-level positive airway pressure (BPAP)
Description: Overlap patients randomized to BPAP will be titrated as per American Academy of Sleep Medicine (AASM) guidelines and oxygen if needed based on saturations \<88% while on stable bi-level settings.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nocturnal oxygen
Description: Oxygen will be titrated to keep resting oxygen saturation (as measured by pulse oximeter) more than 88 percent. The duration of therapy will be six months.
Study: NCT04304196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEMPO
Description: TEMPO is designed as a 7- to 10-week, web-based intervention containing 5 modules to pace patient-caregiver dyads' learning, avoid information overload, and allow sufficient practice time in-between modules . Each module is organized along six key components: needs assessment, tailored information and skills training, goal setting and action planning, motivational and social support, monitoring, automated feedback, and addressing time demands. Overall, modules aim to a) increase dyads' confidence in using strategies to address key psychosocial issues in the acute survivorship phase (e.g., dealing with stress and worry, communicating with partner and family, uncertainty management) and b) assist dyads in developing the self-regulatory skills necessary to meet the physical activity guidelines. Each module specifies a series of online (i.e. didactic material and interactive worksheets) and offline activities (i.e. practicing the proposed skills).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Patients will receive usual care throughout the study. Dyads in this group will not receive any information resources from the research team, but will have access to all of those available at their participating center (sites will be asked to provide a description of usual care practices). Participants will be given access to the TEMPO website after having completed their final questionnaire, as thanks for participating.
Study: NCT04349098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Participants will receive 20 mg of selinexor.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 20 mg of placebo matched to selinexor.
Study: NCT04126785

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Exercise in Heated Water-Based
Description: High intensity interval exercise will perform at controlled heated water-base (30 e 32 ºC). Subject will be submerged at the xiphoid process level. The session will consist in 4 min walking (warm-up) at 9 level of rate perceived exertion (RPE) scale, followed by 21 min of HIIE, alternating 1 min of jogging/running at 15-17 (hard-very hard) level with 2 min of walking at 9-11 (very light-fairly light) level of RPE.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Moderate Exercise in Heated Water-Based
Description: Continuous moderate exercise will perform at controlled heated water-base (30 e 32 ºC). Subject will be submerged at the xiphoid process level. The session will consist in 4 min walking (warm-up) at 9 level (light) of RPE, followed by 26 min of MICE, walking at 11-13 (fairly light)level of RPE.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: CON session will perform at controlled heated water-base (30 e 32 ºC). Subject will be seated in a chair and submerged at the until xiphoid process level for 30 min.
Study: NCT00983801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Vial, Injection, Intravenous (IV), 40 mg/m\^2, Every 21 days, Up to 8 cycles or until disease progression or intolerable toxicity. Additional treatment was given in agreement by both the investigator and sponsor. Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV infusion on Day 1 of each 21-day (3 week) cycle provided the participant met the retreatment criteria.
Study: NCT03921905

Intervention type: DIAGNOSTIC_TEST
Intervention: ABI measurement
Description: ABI measurement wil be done with an automatic device to diagnose PAD in patients with CAD
Study: NCT04022213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131 I-omburtamab
Description: Single dose of IP RIT administered through an IP catheter with 131 I-omburtamab at 80mCi/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131 I-omburtamab
Description: Single dose of IP RIT administered through an IP catheter with 131 I-omburtamab at 80mCi/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131 I-omburtamab
Description: Single dose of IP RIT administered through an IP catheter with 131 I-omburtamab at 80mCi/m2

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: WAP-IMRT
Description: Group A participants will receive WAP-IMRT approximately 2-4 weeks after completing IP RIT. A dose of 30 Gy will be delivered in 20 fractions of 1.5 Gy given once daily, 5 days per week over the course of approximately 4 weeks
Study: NCT04573478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atrasentan
Description: Film-coated tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet
Study: NCT01127958

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCI with a drug-eluting balloon
Description: PCI with a drug-eluting balloon for in-stent restenosis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCI with a drug-eluting stent
Description: PCI with a drug-eluting stent for in-stent restenosis
Study: NCT00779090

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar recruitment manoeuvre
Description: Increase airway pressure during pressure controlled ventilation up to peak-airway pressure of 40 cmH20 and PEEP of 15 cmH20.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar recruitment manoeuvre
Description: Increase airway pressure during pressure controlled ventilation up to peak-airway pressure of 40 cmH20 and PEEP of 15 cmH20.
Study: NCT03707340

Intervention type: DRUG
Intervention: Flibanserin Pill
Description: Eligible participants will begin treatment with flibanserin 100 mg orally daily at bedtime for 24-36 weeks and followed for a total of 52 weeks.
Study: NCT03492385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB2452 Infusion
Description: 30 minute - 12 hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB2452 Infusion
Description: 30 minute - 12 hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB2452 Infusion
Description: 30 minute - 12 hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB2452 Infusion
Description: 30 minute - 12 hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB2452 Infusion
Description: 30 minute - 12 hour infusion
Study: NCT05413031

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: relative motion splint
Description: splint with ability to move the fingers

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: static splint
Description: splint with immobility of wrist, and fingers
Study: NCT04171284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT-I10
Description: 200 mg, Q3W, maximum treatment up to six cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT-I10
Description: 200 mg, Q3W, maximum treatment up to six cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 70-75mg per square meters of body surface area, Q3W, maximum treatment up to six cycles
Study: NCT03492385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB2452 Infusion
Description: 30 minute - 12 hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB2452 Infusion
Description: 30 minute - 12 hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB2452 Infusion
Description: 30 minute - 12 hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB2452 Infusion
Description: 30 minute - 12 hour infusion
Study: NCT04171284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 70-75mg per square meters of body surface area, Q3W, maximum treatment up to six cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200 mg, Q3W, maximum treatment up to six cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 200 mg, Q3W, maximum treatment up to six cycles
Study: NCT02526173

Intervention type: PROCEDURE
Group type: OTHER
Intervention: RALP using full nerve sparing technique
Description: RALP using full nerve sparing technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RALP using full nerve sparing technique
Description: RALP using full nerve sparing technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dHACM Application
Description: 2x12 sheet of dHACM applied to the neurovascular bundle
Study: NCT03516617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03492385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB2452 Infusion
Description: 30 minute - 12 hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Sodium Chloride
Description: 30 minute - 12 hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Sodium Chloride
Description: 30 minute - 12 hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Sodium Chloride
Description: 30 minute - 12 hour infusion
Study: NCT03516617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Observation
Description: Undergo observation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01347307

Intervention type: RADIATION
Group type: OTHER
Intervention: SBRT for Benign Extradural Spine Tumors
Description: 14-25 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)
Study: NCT01587872

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fujinon EC-450BI5 double-balloon colonoscope
Description: Colonoscopy with the test instrument
Study: NCT01539837

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferiprone 20mg
Description: 20mg/kg/d Deferiprone divided into two equal doses (morning and evening), every day for 6 months
Study: NCT03492385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Sodium Chloride
Description: 30 minute - 12 hour infusion
Study: NCT01347307

Intervention type: RADIATION
Group type: OTHER
Intervention: SBRT for Vertebral/Paraspinal Metastases
Description: 12-16 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)
Study: NCT00497276

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: placement of popliteal catheter
Description: Bolus naropin 7,5 mg/ml 30 ml; infusion bupivacaine 2,5 mg/ml 5-10 ml/h

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: placement of popliteal catheter
Description: Bolus naropin 7,5 mg/ml 30 ml; infusion bupivacaine 2,5 mg/ml 5-10 ml/h
Study: NCT01752491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbate
Description: Intravenous infusion of high-dose ascorbate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbate
Description: Intravenous infusion of high-dose ascorbate
Study: NCT01539837

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Feriprox placebo administered orally at the same dosing volume as the 20mg/kg/day feriprox per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferiprone 30mg
Description: 30mg/kg/d Deferiprone divided into two equal doses (morning and evening), every day for 6 months
Study: NCT01752491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbate
Description: Intravenous infusion of high-dose ascorbate
Study: NCT03492385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Sodium Chloride
Description: 30 minute - 12 hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Sodium Chloride
Description: 30 minute - 12 hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Sodium Chloride
Description: 30 minute - 12 hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Sodium Chloride
Description: 30 minute - 12 hour infusion
Study: NCT01752491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbate
Description: Intravenous infusion of high-dose ascorbate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbate
Description: Intravenous infusion of high-dose ascorbate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbate
Description: Intravenous infusion of high-dose ascorbate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Oral chemotherapeutic
Study: NCT03492385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Sodium Chloride
Description: 30 minute - 12 hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Sodium Chloride
Description: 30 minute - 12 hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor Oral Tablet - Pre-Treatment
Description: Ticagrelor 180 mg + 90 mg BID for 5 doses prior to MEDI2452 (PB2452) or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor Oral Tablet - Pre-Treatment
Description: Ticagrelor 180 mg + 90 mg BID for 5 doses prior to MEDI2452 (PB2452) or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor Oral Tablet - Pre-Treatment
Description: Ticagrelor 180 mg + 90 mg BID for 5 doses prior to MEDI2452 (PB2452) or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor Oral Tablet - Pre-Treatment
Description: Ticagrelor 180 mg + 90 mg BID for 5 doses prior to MEDI2452 (PB2452) or Placebo
Study: NCT01752491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Oral chemotherapeutic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Oral chemotherapeutic
Study: NCT03492385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor Oral Tablet - Pre-Treatment
Description: Ticagrelor 180 mg + 90 mg BID for 5 doses prior to MEDI2452 (PB2452) or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment
Description: Ticagrelor 180 mg + 90 mg BID for 5 doses prior to MEDI2452 (PB2452) or Placebo and Ticagerlor 180 mg 24 hours following MEDI2452 (PB2452) or Placebo
Study: NCT01752491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Oral chemotherapeutic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Oral chemotherapeutic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Oral chemotherapeutic
Study: NCT00461955

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous peripheral blood stem cell transplantation, ex vivo amplified
Description: autologous peripheral blood stem cell transplantation, ex vivo amplified
Study: NCT01752491

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: External beam radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: External beam radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: External beam radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: External beam radiation therapy
Study: NCT03897270

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photoacoustic Imaging
Description: Undergo photoacoustic imaging of the breast
Study: NCT02076009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab 16mg/kg will be administered as an intravenous (IV) infusion (into the vein) as per the following schedule: once a week during treatment cycles 1 and 2; every 2 weeks during treatment cycles 3 to 6; and every 4 weeks for cycles 7 and onwards. Following amendment 8, participants receiving daratumumab IV have the option to switch to daratumumab subcutaneous (SC) 1800 mg/dose until documented progression, unacceptable toxicity, or the end of study on Day 1 of any cycle, at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered at a dose of 25 mg orally (by mouth) on Days 1 through 21 of each treatment cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide will be administered at a dose of 25 mg orally (by mouth) on Days 1 through 21 of each treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone (or equivalent in accordance with local standards) will be administered as a total dose of 40 mg weekly (or 20 mg weekly for participants \> 75 years old or with a body mass index \< 18.5).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone (or equivalent in accordance with local standards) will be administered as a total dose of 40 mg weekly (or 20 mg weekly for participants \> 75 years old or with a body mass index \< 18.5).
Study: NCT06637553

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Adlay formula
Description: The extract will be administered at a dose of 20 grams dissolved in 200cc of hot water once daily

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same weight as the adlay formula but did not include the active compound
Study: NCT04072354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856 50mg
Description: SEP-363856 50mg tablet dosed once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856 75mg
Description: SEP-363856 75mg tablet dosed once daily
Study: NCT01752491

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: External beam radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: External beam radiation therapy
Study: NCT03084510

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotus Edge™ Valve System
Description: • The Lotus Edge™ Valve System consisting of two main components:~* a bioprosthetic bovine pericardial aortic valve, and~* a delivery system Device sizes include 23 mm, 25 mm and 27 mm diameter.
Study: NCT00595075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 8 mg tablet by mouth x 1 dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo identical in appearance to active experimental drug x 1 dose
Study: NCT06542341

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: decoLITE (TN2037)
Description: Red/Near infra red light therapy
Study: NCT03060707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium Bromide
Description: Continuously infuse, or bolus administer rocuronium.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium Bromide
Description: Continuously infuse, or bolus administer rocuronium.
Study: NCT04067622

Intervention type: DEVICE
Group type: OTHER
Intervention: Exersides
Description: A novel arm restraint which permits arm mobility but prohibits hands from reaching oral/nasal endotracheal and feeding tubes or intravenous lines.

Intervention type: DEVICE
Group type: OTHER
Intervention: Exersides
Description: A novel arm restraint which permits arm mobility but prohibits hands from reaching oral/nasal endotracheal and feeding tubes or intravenous lines.
Study: NCT02396927

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D HD laparoscopy
Description: Olympus 3D laparoscopy ENDOEYE FLEX in high definition with the use of passive, polarizing glasses.
Study: NCT04420182

Intervention type: OTHER
Group type: OTHER
Intervention: Virtual Care at Home
Description: Participants will have access to the VIRTUES platform for COVID-19 Virtual Care at Home
Study: NCT00489359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed - Phase 1
Description: 500, 600, 700, 800, or 900 milligrams per square meter (mg/m\^2), administered intravenously (IV), every 21 days x 6 cycles, dose escalate to Maximum Tolerated Dose (MTD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin - Phase 1
Description: area under the concentration time curve (AUC) 5 or 6 mg/mL\*min, administered intravenously (IV), every 21 days x 6 cycles, dose escalation to Maximum Tolerated Dose (MTD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed - Phase 2
Description: Dose determined from Phase 1: 500 mg/m\^2, administered IV, every 21 days x 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin - Phase 2
Description: Dose determined from Phase 1: AUC 6 mg/mL\*min, administered IV, every 21 days x 6 cycles